Clinical Updates
Alzheimer's
Disease
Arthritis
Asthma
Benign Prostatic Hypertrophy
Chronic
Lymphocytic Leukemia
Coronary Artery Disease
Depression
Diabetes Mellitus
Dyspepsia
Erectile
Dysfunction
Fatty Liver
Gallstone
Hepatitis
Hypertension
Lung Cancer
Mesothelioma
Metabolic Syndrome
Obesity
Pneumonia
Prostate Cancer
Stroke
Sinusitis
Tinnitus
Medical Library
Breaking Medical News
Clinical Tools
Dermatology
Diabetes Corner
Evidence-Based Medicine
Free Medical Books
Free
Medical Journal
History Taking and Physical Examination
Medical Journal (popular)
Medical Notes
Medical Organizations
Palm Tools
Medical Physiology (Lecture)
Medical Resources
Medical Search
Online Clinical Calculator |
Women's sexual function improves
when partners are administered vardenafil for erectile
dysfunction
|
There are limited data concerning the sexual function of women whose male
partners receive pharmacological treatment for erectile dysfunction (ED).
AIM:
One objective of this research was to prospectively compare the efficacy of
vardenafil vs. placebo administered to men with ED in improving men's and
women partners' sexual function and satisfaction. Another goal was to assess
the relationship of erectile function changes in men with ED receiving
treatment with sexual function changes in women partners not directly
receiving treatment.
METHODS:
A randomized, double-blind, placebo-controlled, multi-institutional
comparison of vardenafil vs. placebo was performed in 229 couples (treated
man with ED>6 months and untreated woman partner). Co-primary outcomes for
which this research was statistically powered were Sexual Encounter Profile
(SEP3) (treated man with ED) and Sexual Life Quality Questionnaire (mSLQQ-QOL)
(untreated woman partner).
MAIN OUTCOME MEASURES:
Erectile function changes in men with ED receiving vardenafil vs. placebo
were compared at last observation carried forward (LOCF) in SEP3,
International Index of Erectile Function (IIEF-EF) and Erection Quality
Scale (EQS). Sexual function at LOCF in women partners was determined by
mSLQQ-QOL and Female Sexual Function Index (FSFI).
RESULTS:
Compared with placebo at LOCF, vardenafil significantly increased least
square (LS) mean scores in: (i) overall per-treated male SEP3 success rate,
IIEF-EF, and EQS; and (ii) mSLQQ-QOL, total FSFI and sexual desire,
subjective arousal, lubrication, orgasm and satisfaction FSFI domains in
untreated women partners. Treatment-related improvement in erectile function
as assessed by IIEF-EF and EQS was correlated reliably with improvement in
women partners' FSFI total and individual domain scores.
CONCLUSIONS:
Vardenafil is an effective ED treatment in men that also significantly
improves sexual function/satisfaction in untreated women partners. Women
partners' sexual function improvements relate significantly and consistently
to treatment-related improvements in men's erectile function. ED management
should emphasize both members of the couple.
Reference:
J Sex Med. 2005 Nov;2(6):819-32. |
|